Related Experiment Video
Updated: Aug 21, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Diabetes mellitus among parkinsonian patients treated chronically with clozapine
Hubert H Fernandez1, Joseph H Friedman, M Cecilia Lansang
1Department of Neurology, University of Florida, Gainesville, FL, USA. fernandez@neurology.ufl.edu
Abstract:
Clozapine is the gold standard treatment for Parkinson's disease (PD) psychosis based on double blinded, placebo controlled trials, and has also been shown to alleviate tremor and dyskinesia. There is accumulating data suggesting that clozapine may be associated with increased frequency of diabetes mellitus (DM) compared to conventional neuroleptic drugs in treating schizophrenia. Forty-four predominantly geriatric parkinsonian subjects on clozapine for psychosis, tremor or dyskinesia, on an average dose of 50.6 mg/d for a mean duration of 41 months were reviewed. The prevalence of DM in this cohort was 18.1% (8/44). This rate was similar to that reported in the aged-matched general population (prevalence = 19.3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Type I Diabetes III: Clinical Manifestations
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Type I Diabetes II: Pathophysiology